Taylor 1982.

Methods	TRIAL DESIGN: Nonrandomised open‐label trial DURATION: 12 months
Participants	COUNTRY: United Kingdom. SETTING: outpatient. Treatment N: 23. Control N: 71. Age: 51‐52 years. Treatment sex: 43% men. Control sex: 77% male. Inclusion: Type 2 DM, obese and nonobese. Exclusions: renal or hepatic disease.
Interventions	TREATMENT: Metformin (obese) 500mg TID. COMPARISON: glibenclamice (nonobese) 2.5‐15mg/day.
Outcomes	Lipids and apolipoproteins
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	D ‐ Not used